This company listing is no longer active
Idogen Management
Management criteria checks 1/4
Idogen's CEO is Christina Herder, appointed in Sep 2022, they has a tenure of less than a year. Their total yearly compensation is SEK454.00K , comprised of 66.1% salary and 33.9% bonuses, including company stock and options. They directly owns 0.06% of the company’s shares, worth SEK7.56K. The average tenure of the management team and the board of directors is 1.5 years and 2.7 years respectively.
Key information
Christina Herder
Chief executive officer
kr454.0k
Total compensation
| CEO salary percentage | 66.1% |
| CEO tenure | less than a year |
| CEO ownership | 0.06% |
| Management average tenure | 1.5yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -kr44m |
| Dec 31 2022 | kr454k | kr300k | -kr48m |
| Sep 30 2022 | n/a | n/a | -kr50m |
| Jun 30 2022 | n/a | n/a | -kr41m |
| Mar 31 2022 | n/a | n/a | -kr39m |
| Dec 31 2021 | kr150k | n/a | -kr39m |
| Sep 30 2021 | n/a | n/a | -kr33m |
| Jun 30 2021 | n/a | n/a | -kr33m |
| Mar 31 2021 | n/a | n/a | -kr31m |
| Dec 31 2020 | kr150k | n/a | -kr27m |
Compensation vs Market: Christina's total compensation ($USD42.19K) is below average for companies of similar size in the Swedish market ($USD231.64K).
Compensation vs Earnings: Christina's compensation has increased whilst the company is unprofitable.
CEO
Christina Herder (62 yo)
less than a year
Tenure
kr454,000
Compensation
Dr. Christina Herder, Ph D., served as Independent Director for Ziccum AB (publ) since April 28, 2022 until May 2023. She is Director at Beactica AB since 2021.She is a Director at Elicera Therapeutics AB...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Director | less than a year | kr454.00k | 0.060% SEK 7.6k | |
| Founder & Chairman of the Scientific Advisory Board | no data | kr150.00k | 0.17% SEK 22.0k | |
| Chief Financial Officer | 7.2yrs | no data | 0.33% SEK 42.1k | |
| Chief Technology Officer | 9.5yrs | kr120.74k | 0.012% SEK 1.5k | |
| Chief Medical Officer | 1.5yrs | no data | no data | |
| Chief Regulatory Officer | 1.3yrs | no data | no data |
1.5yrs
Average Tenure
62yo
Average Age
Experienced Management: IDOGEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Director | 6.2yrs | kr454.00k | 0.060% SEK 7.6k | |
| Founder & Chairman of the Scientific Advisory Board | 7.8yrs | kr150.00k | 0.17% SEK 22.0k | |
| Independent Chairman of the Board | 7.3yrs | kr407.00k | 0.15% SEK 18.9k | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Independent Director | 3.2yrs | kr150.00k | 0.089% SEK 11.1k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
2.7yrs
Average Tenure
64.5yo
Average Age
Experienced Board: IDOGEN's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.